These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23720716)

  • 1. Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitors.
    Lin YC; Happer M; Elder JH
    J Virol; 2013 Aug; 87(15):8524-34. PubMed ID: 23720716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.
    Lin YC; Torbett BE; Elder JH
    J Virol; 2010 Jul; 84(13):6799-809. PubMed ID: 20410281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
    Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
    J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease.
    Lin YC; Perryman AL; Olson AJ; Torbett BE; Elder JH; Stout CD
    Acta Crystallogr D Biol Crystallogr; 2011 Jun; 67(Pt 6):540-8. PubMed ID: 21636894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease.
    Lin YC; Beck Z; Lee T; Le VD; Morris GM; Olson AJ; Wong CH; Elder JH
    J Virol; 2000 May; 74(10):4710-20. PubMed ID: 10775609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
    Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
    J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease.
    Li M; Morris GM; Lee T; Laco GS; Wong CH; Olson AJ; Elder JH; Wlodawer A; Gustchina A
    Proteins; 2000 Jan; 38(1):29-40. PubMed ID: 10651036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.
    Heaslet H; Lin YC; Tam K; Torbett BE; Elder JH; Stout CD
    Retrovirology; 2007 Jan; 4():1. PubMed ID: 17212810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
    Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
    Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.
    Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH
    Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
    Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
    Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
    Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
    Lambert-Niclot S; Flandre P; Canestri A; Peytavin G; Blanc C; Agher R; Soulié C; Wirden M; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Feb; 52(2):491-6. PubMed ID: 18039922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.
    Sasková KG; Kozísek M; Rezácová P; Brynda J; Yashina T; Kagan RM; Konvalinka J
    J Virol; 2009 Sep; 83(17):8810-8. PubMed ID: 19535439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
    Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.
    Eche S; Kumar A; Sonela N; Gordon ML
    Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33805099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the co-evolutionary molecular mechanisms of resistance in the HIV-1 Gag and protease.
    Marie V; Gordon M
    J Biomol Struct Dyn; 2022; 40(21):10852-10861. PubMed ID: 34253143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.
    Stray KM; Callebaut C; Glass B; Tsai L; Xu L; Müller B; Kräusslich HG; Cihlar T
    J Virol; 2013 Jan; 87(1):454-63. PubMed ID: 23097440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.
    Beck ZQ; Lin YC; Elder JH
    J Virol; 2001 Oct; 75(19):9458-69. PubMed ID: 11533208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.
    Palma AC; Covens K; Snoeck J; Vandamme AM; Camacho RJ; Van Laethem K
    J Antimicrob Chemother; 2012 May; 67(5):1075-9. PubMed ID: 22331593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.